From February 2014 to 2016, we recruited 80 patients with malignant glioma in the Renmin Hospital of Wuhan University. To study the effect of radiotherapy and chemotherapy on the levels of serum S100 calcium-binding protein B (S100B), interleukin 6 (IL-6), and interleukin 17 (IL-17), all patients were divided into two groups randomly and evenly. In one group, all 40 patients received the three-dimensional conformal radiotherapy (3D-CRT). In another group, all patients received combinatorial treatment of 3D-CRT and temozolomide (TMZ). The therapeutic effect, immune function index before and after the treatment, change of serum S100B, IL-6, and IL-17 levels as well as adverse reactions were analyzed and compared between those two groups. We found that the effective rate of the combination group was 82.5%, which is significantly higher than 52.5% in the control group. After treatment, the number of CD3+, CD4+, and NK cells in the combination group was higher. But, CD8+ cells were lower compared with those before treatment. The levels of serum S100B, IL-6, and IL-17 in both groups were lower than those before treatment. In conclusion, radiotherapy combined with chemotherapy is more effective than radiotherapy alone in the treatment of malignant cerebral gliomas and is worthy of clinical spreading.
Introduction
Glioma is one of the most common malignant brain tumors characterized by high mortality and high recurrence rate. Generally, glioma is treated with surgery in clinical practices. But, the infiltrative growth of tumor makes it difficult to achieve complete resection through operation. 1 With the development of three-dimensional conformal radiotherapy (3D-CRT), the treatment effect of malignant glioma of brain has been significantly improved. Although postoperative radiotherapy reduces the recurrence rate and improves the survival rate in patients, it is still unsatisfactory in terms of the prognosis of malignant glioma, especially those in stage III-IV. 2 The patients with high-grade glioma can survive only 3 months averagely with high postoperative recurrence rate. At the end of last century, temozolomide was discovered as a new chemotherapeutic drug, which was found to be effective in the treatment of malignant glioma when combined with radiotherapy. 3 Tumor microenvironment plays an important role in tumor invasion and metastasis, which can be promoted by the abnormal inflammatory environment. 4 Many studies have shown that 5 S100 calcium-binding protein B (S100B), interleukin 6 (IL-6), and interleukin 17 (IL-17) are widely expressed in various tumor microenvironments, such as esophageal squamous cell carcinoma and cervical cancer. However, the effects of postoperative radiotherapy and chemotherapy on serum S100B, IL-6, and IL-17 in patients with malignant glioma have not been studied yet. In our study, we compared the efficacy of radiotherapy alone and radiotherapy combined with chemotherapy in the treatment of III and IV grade malignant glioma, with the details reported as below.
Materials and methods

General information
The patients with malignant glioma treated in our hospital from February 2014 to July 2016 were selected as the research objects. They were diagnosed with III or IV high-grade glioma and were given total resection or subtotal resection under the endoscope. After discharge, the patients were followed up for 3 months. They were divided into two groups based on different therapies applied after the operation. A consent has been informed and signed by all patients who participate into our study.
Treatment
Patients in the control group were treated with 3D-CRT. The specific procedure was first designed using CMS TPS software. The patient's head was fixed with headstock, headrest, and thermoplastic molding followed by computed tomography (CT) scan of the whole brain with continuous enhancement, 3 mm/layer in thickness; after scanning, the data were transformed into the software to depict gross tumor volume including tumors and edema which were defined before operation, and clinical target volume was defined as the extension of 2-3 cm away from the entire surgical margin or edema edge. The design of radiation field and dose was evaluated by means of software to ensure that 95% of the radiation dose covered the tumor target volume. In each time of radiotherapy, it was 2 Gy in dose, once per day, and 5 days a week. When the dose in clinical target volume reached 50 Gy/25f, the radiation field was narrowed to about 1 cm from the tumor, and then, the radiation dose continued to be increased until the total dose of Gy/35f. The radiation therapy lasted a total of 7 weeks.
Patients in the study group were given radiotherapy and chemotherapy, in which the treatment planning of radiotherapy was the same as in the control group, and they were additionally treated with oral temozolomide at the dose of 70 mg/ (m 2 day) for chemotherapy. After radiotherapy, the dose was changed to 175 (m 2 day), with the duration of constant 5 days, each course included a 28-day treatment, and patients were treated for a total of six courses. According to individual differences, patients in the two groups underwent antihypertensive treatment with drugs like mannitol and dexamethasone in the process.
Evaluation criteria of efficacy and adverse reactions
The short-term efficacy was evaluated as follow according to the criteria established by World Health Organization (WHO) (1989): (1) complete remission (CR): the tumor completely disappeared and it lasted at least more than 4 weeks with no appearance of new lesions; (2) partial remission (PR): the tumor volume was reduced more than 50%, and it lasted at least more than 4 weeks with no appearance of new lesions; (3) normal condition (NC): the tumor volume was reduced less than 50%, or increased more than 25%; (4) progressive disease (PD): the tumor volume was increased more than 25% or there was the emergence of new lesions. The total effective rate (RR: CR plus PR) was the ratio of CR cases plus PR cases to total cases.
According to the US National Cancer Institute, the side effects of anticancer drugs are classified as I grade (mild): with no influence on normal life; II grade (moderate): with tolerable influence on life; III grade (severe): with intolerable reaction and the need of treatment; and IV grade (critical): with the reaction threatening life.
Observation index
(1) Observation was conducted in the two groups on the changes of cellular immune function before and after treatment, including T cell subsets and NK cells; (2) The changes of serum S100B, IL-6, and IL-17 levels were observed before and after treatment in the two groups, and peripheral venous blood (3 mL) were collected from patients, respectively, before treatment and after treatment followed by the separation of serum, restored at subzero 20°C for measurement; (3) the short-term efficacy after 2-3 months of treatment was observed in the two groups; and (4) the occurrence of adverse reactions during the treatment was observed in the two groups.
Statistical analysis
SPSS v.21 statistical software was used for data analysis. The measurement data were checked by t-test and described as mean ± standard deviation. The counting data were analyzed by chi-square test. P < 0.05 suggests that the difference is statistically significant.
Results
Comparison of short-term efficacy between two groups
The total effective rate of the combination group was 82.5%, significantly higher than that of the control group that was 52.5% (Table 1) .
Comparison of immune function index between the two groups before and after treatment
Before treatment, there was no significant difference in the levels of CD3+, CD4+, CD8+, and NK cells between the two groups. However, after treatment, CD3+, CD4+, and NK cells in the study group were significantly higher. The number of CD8+ cells was significantly lower compared with those before treatment. In the control group, CD3+, CD4+, and NK cells were significantly lower and CD8+ cells was significantly higher compared with those before treatment ( Table 2) .
Comparison of the levels of serum S100B, IL-6, and IL-17 between the two groups before and after treatment
Before treatment, there was no significant difference in the level of serum S100B, IL-6, and IL-17 between two groups. After treatment, the level of serum S100B, IL-6, and IL-17 in two groups was significantly lower than that before treatment ( Table 3) .
Comparison of adverse reactions between the two groups
The adverse reactions were mainly bone marrow depression, nausea, vomiting, and headache of I-II grade and several cases suffering from mild liver damage, which was alleviated by symptomatic treatment of increased white blood cells, dehydration, antiemetic, and liver protection. The incidence of I-II grade adverse reactions was 30% (12/40) in the study group, and in the control group, it was 32.5% (13/40). 
Discussion
Glioma is the most common primary intracranial tumor originating from glial cells and mainly includes such four pathological types as astrocytomas, oligodendrocytes, ependymoma, and mixed gliomas. In the classification of tumors of the central nervous system by WHO, gliomas are divided as I-IV grade in which the gliomas of grades III and IV are malignant ones, accounting for 77.5% of all. 6, 7 Its clinical features are mainly characterized by symptoms and signs of intracranial hypertension and neurological deficit. 8 A variety of drugs have been applied singly or in combination with chemotherapy for malignant glioma. Temozolomide, developed in recent years, is a new type of second-generation alkylating agent imidazotetrazine derivatives, which is rapidly absorbed after oral administration and able to enter cerebrospinal fluid through the blood-brain barrier with effective drug concentration in the central nervous system and takes effect in various stages of tumor cell division and proliferation. 9 Temozolomide, as antitumor drug of alkylating agent, has the main side effects of bone marrow depression and gastrointestinal reactions, but with less toxicity and no accumulation, and the bone marrow suppression can also be reversed, allowing continuous treatment and adding course of treatment. 10 According to the study results, the incidence of grade I-II adverse reactions was 30% in the study group and 32.5% in the control group.
Cellular immunity mediated by T cells plays a leading role in the process of tumor healing. According to different differentiation antigen on the surface of T cell, there are two sub-groups of CD4+ helper T cell and CD8+ effector T cell, both of which play an important role in the body's antitumor and immune regulation. Patients with malignant tumors are often in immunosuppression state and the decline of immune function leads to disorder of T lymphocyte subsets in which CD3+ and CD4+ cells are significantly decreased while CD8+ cells are relatively increased. 11 IL-6, originating from fibroblasts, macrophages, B lymphocytes, and T lymphocytes, has multiple biological functions, participates in the function regulation, differentiation, and growth of a variety of cells and plays an important role in inflammation and immune response. S100B as a calciumbinding protein widely distributed in the central nervous system, is of brain specific expression, and its index is seen to be significantly increased in cerebral embolism, cerebral apoplexy, cerebral injury, and brain malignancies, serving as an evaluation for the prognosis of patients with cerebral hypoxia or brain tumor. Studies have confirmed that 12 IL-17 is involved in the occurrence and development of various tumors such as gastric cancer and ovarian cancer. It is shown in the study that the level of serum S100B, IL-6, and IL-17 in the two groups was significantly lower after treatment than that before treatment. These suggest that the combination of radiotherapy and chemotherapy can significantly reduce the levels of S100B, IL-6, and IL-17 in serum. So, it is guessed that radiotherapy combined with chemotherapy alleviates the condition of malignant glioma in brain by reducing the level of serum S100B, IL-6, and IL-17 in patients.
In conclusion, radiotherapy combined with chemotherapy is more effective than radiotherapy alone in the treatment of malignant cerebral gliomas and is worthy of clinical spreading because it improves the immune function index of patients more obviously and reduces the levels of serum S100B, IL-6, and IL-17 more significantly with less adverse reactions.
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